🔍 Intelligence Synthesis JP/EN
Ethics · Regulation · Technology — Pharma Practice Notes

AI and Cancer Research ── Prostate ── 2026-09-30

Backlit threads under glass lie calm, except one bright tangled knot — a metaphor for a hidden rapid-progression signal in low-risk prostate cancer.
What this means, as an image (AI-generated, GPT Image): Doctors may be able to spot which 'low-risk' prostate cancers are actually likely to progress rapidly.Download image (PNG, 2000×800)
Starting from prostate cancers labeled low risk by clinical criteria, multiomics data are merged into a patient-specific network, ZNF268 is identified, and a Rewiring Score linked to progression-free survival and biochemical recurrence flags aggressive tumors. A separate path evaluates whether a digital pathology AI model predicts abiraterone benefit in STAMPEDE phase III trials.
Image abstract — the whole article on one page (click to enlarge)
2 Prostate papers. Lead: A novel multiomics machine learning signature identifies rapid progression in clinically low risk prostate cancer.

Journals covered and how papers are chosen: see the index

Prostate cancer: treatment, trials and AI

← Back to this issue